Literature DB >> 33417636

C-Reactive Protein, Fibrinogen, Leptin, and Adiponectin Levels in Women with Polycystic Ovary Syndrome.

Cagdas Ozgokce1, Erkan Elci2, Recep Yildizhan3.   

Abstract

BACKGROUND AND AIM: We aimed to compare the levels of clinical, biochemical, hormonal, and metabolic parameters as well as serum CRP, fibrinogen, leptin, and adiponectin in cases with PCOS and control group to investigate whether they play a role in the etiology of the syndrome.
MATERIALS AND METHODS: The present study included a total of 90 subjects, 45 subjects were diagnosed with PCOS (n = 45) and 45 subjects served as control group (n = 45). Serum CRP, fibrinogen, leptin, and adiponectin levels were analyzed for each subject.
RESULTS: Serum CRP, fibrinogen, and leptin were found to be higher (statistically significant) in the group with PCOS as compared to the control group (p < 0.05). Serum Adiponectin was higher in the control group (statistically significantly) as compared with the patients in the PCOS group (p < 0.05).
CONCLUSION: CRP and fibrinogen (cardiac risk factor markers) increase in women with PCOS. The levels of leptin which affects metabolism increase, whereas the levels of adiponectin decrease. © Federation of Obstetric & Gynecological Societies of India 2020.

Entities:  

Keywords:  Adiponectin; CRP; Fibrinogen; Leptin; PCOS

Year:  2020        PMID: 33417636      PMCID: PMC7758390          DOI: 10.1007/s13224-020-01331-7

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  32 in total

1.  A novel serum protein similar to C1q, produced exclusively in adipocytes.

Authors:  P E Scherer; S Williams; M Fogliano; G Baldini; H F Lodish
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

Review 2.  Regulation of circulating leptin in humans.

Authors:  B Ahrén; H Larsson; C Wilhelmsson; B Näsman; T Olsson
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

3.  Common Inflammatory Markers in Polycystic Ovary Syndrome (PCOS): A BMI (Body Mass Index)-Matched Case-Control Study.

Authors:  Sudhindra Mohan Bhattacharya; Atreyee Basu
Journal:  J Obstet Gynaecol India       Date:  2018-06-19

Review 4.  Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy.

Authors:  R Homburg
Journal:  Hum Reprod       Date:  1996-01       Impact factor: 6.918

Review 5.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.

Authors:  Anders H Berg; Terry P Combs; Philipp E Scherer
Journal:  Trends Endocrinol Metab       Date:  2002-03       Impact factor: 12.015

6.  Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Joachim Spranger; Matthias Möhlig; Uta Wegewitz; Michael Ristow; Andreas F H Pfeiffer; Thilo Schill; Hans W Schlösser; Georg Brabant; Christof Schöfl
Journal:  Clin Endocrinol (Oxf)       Date:  2004-12       Impact factor: 3.478

7.  Adiponectin levels in women with polycystic ovary syndrome.

Authors:  Francesco Orio; Stefano Palomba; Teresa Cascella; Gabriella Milan; Roberto Mioni; Claudio Pagano; Fulvio Zullo; Annamaria Colao; Gaetano Lombardi; Roberto Vettor
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 8.  Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?

Authors:  Natasha L Brooks; Kelli S Moore; Ryan D Clark; Michael T Perfetti; Chad M Trent; Terry P Combs
Journal:  Diabetes Obes Metab       Date:  2007-05       Impact factor: 6.577

9.  Adiponectin is not altered with exercise training despite enhanced insulin action.

Authors:  Matthew W Hulver; Donghai Zheng; Charles J Tanner; Joseph A Houmard; William E Kraus; Cris A Slentz; Madhur K Sinha; Walter J Pories; Kenneth G MacDonald; G Lynis Dohm
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-10       Impact factor: 4.310

Review 10.  Leptin and the regulation of body weight in mammals.

Authors:  J M Friedman; J L Halaas
Journal:  Nature       Date:  1998-10-22       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.